Advances and pitfalls of specialized pain care through public and private health care providers in Catalonia and the Balearic Islands: a physician's survey
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Medel, Javier
- dc.contributor.author Serrano Afonso, Andrés Ancor
- dc.contributor.author Batet, Carme
- dc.contributor.author Lorente, Lluis
- dc.contributor.author Bella, Susana
- dc.contributor.author Ferrándiz, Marta
- dc.contributor.author Monerris, María-Del-Mar
- dc.contributor.author Boada, Sergi
- dc.contributor.author Villoria, Jesús
- dc.contributor.author Ribera, María Victoria
- dc.contributor.author Montes Pérez, Antonio
- dc.contributor.author Videla, Sebastià
- dc.date.accessioned 2022-11-30T07:42:16Z
- dc.date.available 2022-11-30T07:42:16Z
- dc.date.issued 2022
- dc.description.abstract Objective: metabolic syndrome is a health-threatening condition suffered by approximately one third of schizophrenia patients and largely attributed to antipsychotic medication. Previous evidence reports a common genetic background of psychotic and metabolic disorders. In this study, we aimed to assess the role of polygenic risk scores (PRSs) on the progression of the metabolic profile in a first-episode psychosis (FEP) cohort. Method: Of the 231 FEP individuals included in the study, 192-220 participants were included in basal analysis and 118-179 in longitudinal 6-month models. Eleven psychopathologic and metabolic PRSs were constructed. Basal and longitudinal PRSs association with metabolic measurements was assessed by statistical analyses. Results: no major association of psychopathological PRSs with the metabolic progression was found. However, high risk individuals for depression and cholesterol-related PRSs reported a higher increase of cholesterol levels during the follow-up (FDR ≤ 0.023 for all analyses). Their effect was comparable to other well-established pharmacological and environmental risk factors (explaining at least 1.2% of total variance). Conclusion: our findings provide new evidence of the effects of metabolic genetic risk on the development of metabolic dysregulation. The future establishment of genetic profiling tools in clinical procedures could enable practitioners to better personalize antipsychotic treatment selection and dosage.
- dc.format.mimetype application/pdf
- dc.identifier.citation Medel J, Serrano A, Batet C, Lorente L, Bella S, Ferrandiz M,et al. Advances and pitfalls of specialized pain care through public and private health care providers in Catalonia and the Balearic Islands: a physician's survey. Pain Res Manag. 2022 May 21; 2022: 4077139. DOI: 10.1155/2022/4077139
- dc.identifier.doi http://dx.doi.org/10.1155/2022/4077139
- dc.identifier.issn 1203-6765
- dc.identifier.uri http://hdl.handle.net/10230/55043
- dc.language.iso eng
- dc.publisher Hindawi
- dc.rights Copyright © 2022 Javier Medel et al. This is an open access article distributed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Metabolic syndrome
- dc.subject.keyword Polygenic risk score
- dc.subject.keyword Psychotic disorders
- dc.title Advances and pitfalls of specialized pain care through public and private health care providers in Catalonia and the Balearic Islands: a physician's survey
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion